247 related articles for article (PubMed ID: 30782385)
1. Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab.
Kogure Y; Ishii Y; Oki M
J Thorac Oncol; 2019 Mar; 14(3):e55-e57. PubMed ID: 30782385
[No Abstract] [Full Text] [Related]
2. Tracheoesophageal Fistula Caused by Successful Response to Pembrolizumab in a Patient With Squamous Cell Lung Cancer.
Wang H; Zhang L; Liu W
J Thorac Oncol; 2019 Jul; 14(7):e141-e143. PubMed ID: 31235036
[No Abstract] [Full Text] [Related]
3. Histologic Transformation in a Patient with Lung Cancer Treated with Chemotherapy and Pembrolizumab.
Hsu CL; Chen KY; Kuo SW; Chang YL
J Thorac Oncol; 2017 Jun; 12(6):e75-e76. PubMed ID: 28532567
[No Abstract] [Full Text] [Related]
4. Real-World Experience With Pembrolizumab in Patients With Advanced Lung Cancer.
Peng TR; Wu TW
Am J Ther; 2019; 26(4):e537-e538. PubMed ID: 30946046
[No Abstract] [Full Text] [Related]
5. Fatal encephalopathy after pembrolizumab treatment for advanced non-small cell lung carcinoma.
Freitas C; Sampaio L; Fernandes G
J Neurooncol; 2019 Nov; 145(2):399-402. PubMed ID: 31506753
[No Abstract] [Full Text] [Related]
6. Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer.
Romeo MAL; Garassino MC; Moiola L; Galli G; Comi G; Martinelli V; Filippi M
J Neurol; 2019 Dec; 266(12):3163-3166. PubMed ID: 31586260
[No Abstract] [Full Text] [Related]
7. Pembrolizumab and Severe Hypertriglyceridemia Requiring Apheresis: An Immune-Related Adverse Event.
Thakker M; Quadri K; Desai A; Illyas W; Kim MY; Desai S; Rager C
J Oncol Pract; 2019 Nov; 15(11):613-614. PubMed ID: 31580769
[No Abstract] [Full Text] [Related]
8. Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non-Small Cell Lung Cancer.
Tamura T; Akimoto E; Matsumoto C; Mori S; Nishi T; Kudo K; Kuyama S
J Thorac Oncol; 2018 Oct; 13(10):1606-1607. PubMed ID: 29730378
[No Abstract] [Full Text] [Related]
9. Susac's syndrome as an immune-related adverse event after pembrolizumab: a case report.
De Groot M; Compter A; De Langen AJ; Brandsma D
J Neurol; 2020 Jan; 267(1):282-284. PubMed ID: 31701330
[No Abstract] [Full Text] [Related]
10. Autoimmune-Related Primary Hypoparathyroidism Possibly Induced by the Administration of Pembrolizumab: A Case Report.
Umeguchi H; Takenoshita H; Inoue H; Kurihara Y; Sakaguchi C; Yano S; Hasuzawa N; Sakamoto S; Sakamoto R; Ashida K
J Oncol Pract; 2018 Jul; 14(7):449-451. PubMed ID: 29906213
[No Abstract] [Full Text] [Related]
11. Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab.
Jo H; Yoshida T; Horinouchi H; Yagishita S; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Yamamoto N; Takahashi K; Motoi N; Ohe Y
Cancer Immunol Immunother; 2022 Feb; 71(2):387-398. PubMed ID: 34180007
[TBL] [Abstract][Full Text] [Related]
12. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Vandormael K; Riccio A; Yang J; Pietanza MC; Brahmer JR
J Clin Oncol; 2019 Mar; 37(7):537-546. PubMed ID: 30620668
[TBL] [Abstract][Full Text] [Related]
13. Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab.
Hirabae A; Ichihara E; Sunami R; Ota M; Iwamoto Y; Maeda Y; Kiura K
Acta Med Okayama; 2020 Oct; 74(5):423-425. PubMed ID: 33106698
[TBL] [Abstract][Full Text] [Related]
14. An unknown reaction to pembrolizumab: giant cell arteritis.
Micaily I; Chernoff M
Ann Oncol; 2017 Oct; 28(10):2621-2622. PubMed ID: 28633343
[No Abstract] [Full Text] [Related]
15. Prurigo nodularis and pembrolizumab: A therapeutic challenge.
Fattore D; Panariello L; Annunziata MC; Fabbrocini G
Eur J Cancer; 2019 Mar; 110():8-10. PubMed ID: 30735833
[No Abstract] [Full Text] [Related]
16. Cytokine Release Syndrome Resulting From Anti-Programmed Death-1 Antibody: Raising Awareness Among Community Oncologists.
Adashek ML; Feldman M
J Oncol Pract; 2019 Sep; 15(9):502-504. PubMed ID: 31310573
[No Abstract] [Full Text] [Related]
17. Advanced non-small cell lung cancer - treatment with Pembrolizumab.
Silvinato A; Floriano I; Bernardo WM
Rev Assoc Med Bras (1992); 2020 Mar; 66(3):256. PubMed ID: 32520141
[No Abstract] [Full Text] [Related]
18. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
19. Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer.
Yamagata S; Kageyama K; Takayasu S; Asari Y; Makita K; Terui K; Daimon M
Intern Med; 2019 Dec; 58(24):3557-3562. PubMed ID: 31462588
[TBL] [Abstract][Full Text] [Related]
20. Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy.
Andersson NW; Zachariae C; Simonsen AB
Eur J Cancer; 2021 Mar; 145():168-170. PubMed ID: 33486439
[No Abstract] [Full Text] [Related]
[Next] [New Search]
